Literature DB >> 12214117

Decreased Levels of Amyloid-beta 1-42 in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients.

B. Van Everbroeck1, A.J.E. Green, Ph. Pals, J.J. Martin, P. Cras.   

Abstract

Creutzfeldt–Jakob disease (CJD) is a rare neurodegenerative disease caused by the prion protein. In the search for biochemical markers for CJD, cerebrospinal fluid (CSF) of 101 patients was analysed for 14-3-3 protein, hTau-protein and amyloid-beta 1-42 (Abeta_1-42). The 14-3-3 test had a specificity of 91.5% and a sensitivity of 84%. The hTau test resulted in 95% specificity and 74% sensitivity, when a cut-off of 1530 pg/ml was used. Abeta_1-42 detection in CSF of 29 probable or definite CJD patients revealed significantly decreased values (p=0.01) compared to a group of 22 neurological controls. In the CJD patients a mean of 319+/-102 pg/ml was found. In the neurological control group a mean of 553+/-268 pg/ml was observed. In patients with a false positive 14-3-3 test (n=5) a mean of 716+/-441 pg/ml was found. We conclude that determination of Abeta_1-42 levels in CSF can be useful for identifying false positive 14-3-3 results in suspected CJD patients. We also compared the presence of senile plaques and the Abeta_1-42 levels in CSF of CJD patients. No clear correlation between them was found in this series. This signifies that the deceased Abeta_1-42 levels in CSF are not just due to plaque retention but that other mechanisms must also play a role.

Entities:  

Year:  1999        PMID: 12214117     DOI: 10.3233/jad-1999-1606

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  11 in total

Review 1.  Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Authors:  Courtney L Sutphen; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

2.  Increased incidence of sporadic Creutzfeldt-Jakob disease in the age groups between 70 and 90 years in Belgium.

Authors:  B Van Everbroeck; A Michotte; R Sciot; C Godfraind; M Deprez; S Quoilin; J-J Martin; P Cras
Journal:  Eur J Epidemiol       Date:  2006-07-12       Impact factor: 8.082

3.  Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.

Authors:  Franc Llorens; Niels Kruse; Matthias Schmitz; Mohsin Shafiq; José Eriton Gomes da Cunha; Nadine Gotzman; Saima Zafar; Katrin Thune; João Ricardo Mendes de Oliveira; Brit Mollenhauer; Inga Zerr
Journal:  J Neurol       Date:  2015-07-11       Impact factor: 4.849

4.  ApoE distribution and family history in genetic prion diseases in Germany.

Authors:  Anna Krasnianski; Nicolas von Ahsen; Uta Heinemann; Bettina Meissner; Hans A Kretzschmar; Victor W Armstrong; Inga Zerr
Journal:  J Mol Neurosci       Date:  2007-09-11       Impact factor: 3.444

5.  Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.

Authors:  Silvia A Mandel; Micaela Morelli; Ilan Halperin; Amos D Korczyn
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

Review 6.  CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Authors:  K Blennow; E Vanmechelen; H Hampel
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.682

7.  Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD?

Authors:  Constanze Boesenberg-Grosse; Walter J Schulz-Schaeffer; Monika Bodemer; Barbara Ciesielczyk; Bettina Meissner; Anna Krasnianski; Mario Bartl; Uta Heinemann; Daniela Varges; Sabina Eigenbrod; Hans A Kretzschmar; Alison Green; Inga Zerr
Journal:  BMC Neurol       Date:  2006-09-21       Impact factor: 2.474

Review 8.  Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.

Authors:  Marie-Laure Caillet-Boudin; Francisco-Jose Fernandez-Gomez; Hélène Tran; Claire-Marie Dhaenens; Luc Buee; Nicolas Sergeant
Journal:  Front Mol Neurosci       Date:  2014-01-09       Impact factor: 5.639

9.  Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.

Authors:  Samir Abu Rumeileh; Francesca Lattanzio; Michelangelo Stanzani Maserati; Romana Rizzi; Sabina Capellari; Piero Parchi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.

Authors:  Michelle Kokkinou; Lucy C Beishon; Nadja Smailagic; Anna H Noel-Storr; Chris Hyde; Obioha Ukoumunne; Rosemary E Worrall; Anja Hayen; Meera Desai; Abhishekh Hulegar Ashok; Eleanor J Paul; Aikaterini Georgopoulou; Tiziana Casoli; Terry J Quinn; Craig W Ritchie
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.